Literature DB >> 28076701

Reduced Expiratory Flow Rate among Heavy Smokers Increases Lung Cancer Risk. Results from the National Lung Screening Trial-American College of Radiology Imaging Network Cohort.

Raewyn J Hopkins1, Fenghai Duan2, Caroline Chiles3, Erin M Greco2, Greg D Gamble1, Denise Aberle4, Robert P Young1,5.   

Abstract

RATIONALE: Although epidemiological studies consistently show that chronic obstructive pulmonary disease is associated with an increased risk of lung cancer, debate exists as to whether there is a linear relationship between the severity of airflow limitation and lung cancer risk.
OBJECTIVES: We examined this in a large, prospective study of older heavy smokers from the American College of Radiology Imaging Network subcohort of the National Lung Screening Trial (ACRIN). Airflow limitation was defined by prebronchodilator spirometry subgrouped according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 1-4.
METHODS: In the National Lung Screening Trial-ACRIN cohort of 18,473 screening participants, 6,436 had airflow limitation (35%) and 12,037 (65%) had no airflow limitation. From these groups, 758 lung cancer cases were prospectively identified. Participants with airflow limitation were stratified according to GOLD groups 1 (n = 1,607), 2 (n = 3,528), 3 (n = 1,083), and 4 (n = 211). Lung cancer incidence at study end (mean follow-up, 6.4 yr) was compared between the GOLD groups and those with no airflow limitation (referent group).
MEASUREMENTS AND MAIN RESULTS: Compared with those with no airflow limitation, where lung cancer incidence was 3.78/1,000 person years, incidence rates increased in a simple linear relationship: GOLD 1 (6.27/1,000 person yr); GOLD 2 (7.86/1,000 person yr); GOLD 3 (10.71/1,000 person yr); and GOLD 4 (13.25/1,000 person yr). All relationships were significant versus the reference group at a P value of 0.0001 or less.
CONCLUSIONS: In a large prospective study of high-risk cigarette smokers, we report a strong linear relationship between increasing severity of airflow limitation and risk of lung cancer.

Entities:  

Keywords:  National Lung Screening Trial; airflow limitation; chronic obstructive pulmonary disease; lung cancer; risk

Mesh:

Year:  2017        PMID: 28076701      PMCID: PMC5686299          DOI: 10.1513/AnnalsATS.201609-741OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  46 in total

1.  Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease.

Authors:  Sukhwinder S Sohal; David Reid; Amir Soltani; Chris Ward; Steven Weston; H Konrad Muller; Richard Wood-Baker; Eugene H Walters
Journal:  Respirology       Date:  2010-07-12       Impact factor: 6.424

2.  Lung Cancer Screening in Individuals with Chronic Obstructive Pulmonary Disease. Finding the Sweet Spot.

Authors:  Michael K Gould
Journal:  Am J Respir Crit Care Med       Date:  2015-11-01       Impact factor: 21.405

3.  Diagnosing COPD and targeted lung cancer screening.

Authors:  Robert P Young; Raewyn J Hopkins
Journal:  Eur Respir J       Date:  2012-10       Impact factor: 16.671

4.  CT screening in COPD: impact on lung cancer mortality: de Torres JP, Casanova C, Marin JM et al. Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. Respir med 2013; 107: 702-707.

Authors:  R P Young; R J Hopkins
Journal:  Respir Med       Date:  2014-02-12       Impact factor: 3.415

5.  Airways obstruction and the risk for lung cancer.

Authors:  M S Tockman; N R Anthonisen; E C Wright; M G Donithan
Journal:  Ann Intern Med       Date:  1987-04       Impact factor: 25.391

6.  Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study.

Authors:  D J Hole; G C Watt; G Davey-Smith; C L Hart; C R Gillis; V M Hawthorne
Journal:  BMJ       Date:  1996-09-21

Review 7.  Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and meta-analysis.

Authors:  C Carlsten; G S Sagoo; A J Frodsham; W Burke; J P T Higgins
Journal:  Am J Epidemiol       Date:  2008-02-12       Impact factor: 4.897

8.  Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial.

Authors:  Nanda Horeweg; Carlijn M van der Aalst; Erik Thunnissen; Kristiaan Nackaerts; Carla Weenink; Harry J M Groen; Jan-Willem J Lammers; Joachim G Aerts; Ernst T Scholten; Joost van Rosmalen; Willem Mali; Matthijs Oudkerk; Harry J de Koning
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

9.  Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest.

Authors:  Juan P de Torres; Gorka Bastarrika; Juan P Wisnivesky; Ana B Alcaide; Arantza Campo; Luis M Seijo; Jesús C Pueyo; Alberto Villanueva; María D Lozano; Usua Montes; Luis Montuenga; Javier J Zulueta
Journal:  Chest       Date:  2007-12       Impact factor: 9.410

10.  GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?

Authors:  Robert P Young; Raewyn J Hopkins; Bryan A Hay; Gregory D Gamble
Journal:  Appl Clin Genet       Date:  2011-09-13
View more
  18 in total

1.  Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function.

Authors:  Brian J Sandri; Laia Masvidal; Carl Murie; Margarita Bartish; Svetlana Avdulov; LeeAnn Higgins; Todd Markowski; Mark Peterson; Jonas Bergh; Ping Yang; Charlotte Rolny; Andrew H Limper; Timothy J Griffin; Peter B Bitterman; Chris H Wendt; Ola Larsson
Journal:  Am J Respir Crit Care Med       Date:  2019-08-01       Impact factor: 21.405

2.  Optimizing selection of candidates for lung cancer screening: role of comorbidity, frailty and life expectancy.

Authors:  Shailesh Advani; Dejana Braithwaite
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 3.  Chronic obstructive pulmonary disease (COPD) and lung cancer screening.

Authors:  Robert P Young; Raewyn J Hopkins
Journal:  Transl Lung Cancer Res       Date:  2018-06

Review 4.  COPD and the gut-lung axis: the therapeutic potential of fibre.

Authors:  Annalicia Vaughan; Zoe A Frazer; Philip M Hansbro; Ian A Yang
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

Review 5.  Low-Dose CT Screening for Lung Cancer: Evidence from 2 Decades of Study.

Authors:  David S Gierada; William C Black; Caroline Chiles; Paul F Pinsky; David F Yankelevitz
Journal:  Radiol Imaging Cancer       Date:  2020-03-27

6.  Incidental Findings on Low-Dose CT Scan Lung Cancer Screenings and Deaths From Respiratory Diseases.

Authors:  Paul F Pinsky; David A Lynch; David S Gierada
Journal:  Chest       Date:  2021-11-25       Impact factor: 10.262

7.  Xeroderma Pigmentosum Group C Deficiency Alters Cigarette Smoke DNA Damage Cell Fate and Accelerates Emphysema Development.

Authors:  Catherine R Sears; Huaxin Zhou; Matthew J Justice; Amanda J Fisher; Jacob Saliba; Isaac Lamb; Jessica Wicker; Kelly S Schweitzer; Irina Petrache
Journal:  Am J Respir Cell Mol Biol       Date:  2018-03       Impact factor: 6.914

8.  Prevalence, symptom burden and under-diagnosis of chronic obstructive pulmonary disease in Polish lung cancer screening population: a cohort observational study.

Authors:  Aleksandra Undrunas; Piotr Kasprzyk; Aleksandra Rajca; Krzysztof Kuziemski; Witold Rzyman; Tomasz Zdrojewski
Journal:  BMJ Open       Date:  2022-04-11       Impact factor: 2.692

9.  Comorbidity Profiles and Lung Cancer Screening among Older Adults: U.S. Behavioral Risk Factor Surveillance System 2017-2019.

Authors:  Shailesh Advani; Dongyu Zhang; Martin Tammemagi; Tomi Akinyemiju; Michael K Gould; Gerard A Silvestri; Dejana Braithwaite
Journal:  Ann Am Thorac Soc       Date:  2021-11

Review 10.  Lung cancer screening CT-based coronary artery calcification in predicting cardiovascular events: A systematic review and meta-analysis.

Authors:  Lili Fan; Kaikai Fan
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.